STREAGER

STREAGER Study: EBR/GZR for 8 weeks in genotype 1b without severe fibrosis

Abergel A. AASLD 2017, Abs. LB5

Anti-HCV
Grazoprevir
Elbasvir
Genotype
1b
Treatment history
Naive
Cirrhosis
No

DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design


* Fibroscan ® < 9.5 kPa + FibroTest ® < 0.59 or Fibrometer ® < 0.63

  • EBR/GZR: 50/100 mg 1 tablet QD

Objective

  • SVR12, (HCV RNA < LLOQ)

Baseline characteristics and outcome


* Interim analysis on 53 patients
** 2 relapses : 1 patient, F0-F1, with genotype 1b at relapse, emergence of Y93H RAS ; 1 patient, F2, with genotype 1e at relapse, emergence of L28M + R30Q + A92T + Y93H RASs

Safety

  • No adverse event of grade 3 or 4
  • Adverse events >10% related to treatment :
    • Asthenia : 28%
    • Headache : 23%
    • Digestive disorders : 13%

Summary

  • High cure rate (SVR12 98%) was achieved in a treatment-naïve non severe fibrosis GT1b-infected population treated for 8 weeks with the combination of EBR/GZR
  • Good safety profile
  • These results are
    • in agreement with the results obtained in the C-WORTHY study with 8 weeks of EBR/GZR ± RBV (SVR12 of 97%)
    • very similar to those obtained in patients treated 12 weeks with EBR/GZR (SVR12 of 98%)
  • These results are preliminary